Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

Niacin will improve postprandial hyperlipidaemia and cardiovascular risks indices via its lipid lowering as well as via pleiotropic effects in patients with polycystic ovary syndrome (PCOS).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hull and East Yorkshire Hospitals NHS Trust; Hull University Teaching Hospitals NHS Trust
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Females aged between 18 - 50 years

• Has polycystic ovary syndrome diagnosed according to Rotterdam consensus statement

Exclusion Criteria:

• Pregnancy/trying to conceive/breast feeding

• History of cardiovascular, renal, hepatic and active thyroid disease

• History of gout

• History of alcohol abuse

• History of diabetes

• History of allergy to nicotinic acid/laropiprant or food

• History of bleeding disorders/active peptic ulcers

• Patient on antihypertensive medications

• Patient on anticoagulants

• Patient on any hormonal replacement or oral contraceptive pills or cholesterol lowering agents

• History of smoking more than 15 pack year

• Unwilling for GP to be informed